Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 12, 2022 07:00 ET
|
Instil Bio
Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site DELTA-1 trial of ITIL-168 in advanced melanoma with registrational...
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
May 27, 2022 07:00 ET
|
Instil Bio
FDA granted IND clearance for ITIL-306, Instil’s first genetically-engineered CoStAR-TIL therapy for the treatment of NSCLC, RCC, and ovarian cancerInstil to present in vivo data with CoStAR T cells...
Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)
May 18, 2022 07:00 ET
|
Instil Bio
DALLAS, May 18, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...
Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022 07:00 ET
|
Instil Bio
Targeting completion of enrollment in registrational cohort of DELTA-1 in 2022Presenting preclinical efficacy and safety data of CoStAR platform at ASCO 2022Cash runway into 2024 through key clinical...
Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 07, 2022 07:00 ET
|
Instil Bio
- Initiated DELTA-1, a Phase 2 trial of ITIL-168 in advanced melanoma with registrational intent - Received orphan drug and fast-track designation from the U.S. FDA for lead pipeline candidate,...
Instil Bio to Present at the Cowen 42nd Annual Health Care Conference
March 02, 2022 07:00 ET
|
Instil Bio
DALLAS, March 02, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL,...
Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021 07:00 ET
|
Instil Bio
Patients enrolled and recruitment ongoing in Phase 2 trial of ITIL-168 in melanoma (DELTA-1)Fast Track Designation granted by FDA for ITIL-168 in metastatic melanomaCoStAR mechanism of action data...
Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 15, 2021 07:00 ET
|
Instil Bio
DALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...
Instil Bio to Present at Upcoming Investor Conferences in November
November 08, 2021 08:05 ET
|
Instil Bio
DALLAS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...
Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress
September 16, 2021 07:00 ET
|
Instil Bio
DALLAS, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL,...